Corvus Pharmaceuticals (NASDAQ:CRVS) is a biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies. With a deep commitment to harnessing the body's immune system to attack cancer cells, Corvus is at the forefront of developing monoclonal antibodies and small molecule inhibitors aimed at treating a wide range of cancers. These include efforts to combat the most aggressive types of the disease by inhibiting immune checkpoints and other pathways that tumors use to grow and evade detection by the immune system. The company's pipeline is a testament to its innovative approach, featuring lead candidates such as CPI-006, CPI-818, and Mupadolimab, which are in various stages of clinical trials, reflecting the company's objective to offer new hope to patients battling cancer.